Replies to post #89101 on Biotech Values

[iwfal]

They're there to help patients, but they agree to sit on material data for months for a meaningless oral presentation at AHA.

I would argue that that is a different issue - enforced by the medical conferences. The companies actually bristle under that rule - but have no choice if they want the opportunity to make a splash with the people who will ultimately make the decision to prescribe the treatment. Or reward the people running the trials.

>Do you even know of a company that processed an interim that could be used for submission in 1 week? <

No I don't. Not sure that really matters though.

My point was that I don't think the industry knows how to do it. If it is even possible at all (without costing substantially more money to vet the data on a routine basis).